tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF ScreenerTop ETFs by Smart Score
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Aristocrats
New
Dividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Options Profit Calculator
New
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Top ETFs by Smart Score
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Aristocrats
New
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

HUMA Stock Latest News

Humacyte to Present at the Jefferies Healthcare Conference
Press ReleasesHumacyte to Present at the Jefferies Healthcare Conference
18h ago
HUMA
Humacyte First Quarter 2023 Financial Results and Business Update
Press ReleasesHumacyte First Quarter 2023 Financial Results and Business Update
25d ago
HUMA
Humacyte (HUMA) Q1 Earnings Cheat Sheet
Pre-EarningsHumacyte (HUMA) Q1 Earnings Cheat Sheet
27d ago
HUMA
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023
Press ReleasesHumacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023
1M ago
HUMA
Humacyte to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Press ReleasesHumacyte to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
1M ago
HUMA
Humacyte, JDRF collaborating to develop insulin-producing BVP to treat T1D
The FlyHumacyte, JDRF collaborating to develop insulin-producing BVP to treat T1D
1M ago
HUMA
Humacyte management to meet with BTIG
The FlyHumacyte management to meet with BTIG
1M ago
HUMA
Humacyte management to meet with BTIG
The FlyHumacyte management to meet with BTIG
2M ago
HUMA
Humacyte announces publication of preclinical study on HAV to expanded ePTFE
The FlyHumacyte announces publication of preclinical study on HAV to expanded ePTFE
2M ago
HUMA
Humacyte Announces Publication of Preclinical Study Comparing Human Acellular Vessel™ (HAV™) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
Press ReleasesHumacyte Announces Publication of Preclinical Study Comparing Human Acellular Vessel™ (HAV™) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
2M ago
HUMA
Humacyte completes enrollment in Phase 3 trial of HAV for hemodialysis
The FlyHumacyte completes enrollment in Phase 3 trial of HAV for hemodialysis
2M ago
HUMA
Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients
Press ReleasesHumacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel™ (HAV™) for Hemodialysis Access in End-Stage Renal Disease Patients
2M ago
HUMA
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
Press ReleasesHumacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
2M ago
HUMA
Humacyte expects cash to fund operations through 2024
The FlyHumacyte expects cash to fund operations through 2024
2M ago
HUMA
Humacyte reports Q4 EPS (4c), consensus (23c)
The FlyHumacyte reports Q4 EPS (4c), consensus (23c)
2M ago
HUMA
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023
Press ReleasesHumacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023
3M ago
HUMA
BTIG finds medical technology stocks with exposure with SVB
The FlyBTIG finds medical technology stocks with exposure with SVB
3M ago
ATRC
HUMA
Humacyte to Present at Upcoming Investor Conferences in March
Press ReleasesHumacyte to Present at Upcoming Investor Conferences in March
3M ago
HUMA
Humacyte announces publication of 6-year outcomes in Phase 2 study of HAV
The FlyHumacyte announces publication of 6-year outcomes in Phase 2 study of HAV
4M ago
HUMA
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
Press ReleasesHumacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
4M ago
HUMA
Humacyte price target lowered to $5 from $8 at Cowen
The FlyHumacyte price target lowered to $5 from $8 at Cowen
6M ago
HUMA
Humacyte hosts KOL webinar on vascular trauma
The FlyHumacyte hosts KOL webinar on vascular trauma
6M ago
HUMA
iosandroid
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert CenterETF Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksCareersContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.